8/9/2019 Ani Iabetic Drug Final

1/19

PRESENTATION ON PRODUCT

SURVEY OFANTI-DIABETIC AGENTS

Prepared By :Group 7

NiravHirenPunitKeyurMitesh

Bhupendra

8/9/2019 Ani Iabetic Drug Final

2/19

Introduction

Major Players

Product Range

Active Pharmaceutical Ingredient

Anti-diabetic Parental preparations Advertisement

Distribution Channel

Pricing

Conclusion

Reference

8/9/2019 Ani Iabetic Drug Final

3/19

Introduction

What is Diabetes ?

-Metabolic disorder-Characterized by chronic hyperglycemia

8/9/2019 Ani Iabetic Drug Final

4/19

Introduction

What is the purpose ofanti-diabetic agents?

Treat DiabetesManage Blood Sugar

8/9/2019 Ani Iabetic Drug Final

5/19

Major Players

Sa

lesgro

wth,2008

-09

(%)

Sales, 2009 ($bn)

Reference:- Business insights

8/9/2019 Ani Iabetic Drug Final

6/19

Major Players

Major

-ELLY LILLY

-NOVO NORDISK

-USV (us vitamin)

-SUN PHARMA

-TORRENT

-RANBAXY

-ZYDUS CADILA

-CADILA PHARMA

Others

-ALEMBIC

-SARABHAI

-INTAS

-OTSIRA GENETICA

-BAL PHARMA

-AVENTIS

-PANACEA

-DR. REDDYS LAB

-UNISEARCH

-FRANCO INDIAN

-MICRO LAD

8/9/2019 Ani Iabetic Drug Final

7/19

PRODUCT RANGE

Available in various dosage forms and in various quantity ofactive pharmaceutical ingredient.

- Control release tablets

- Sustain release tablets- Extended release tablets

- Semi tablets

- Capsules

- Parental preparation

(Subcutaneous rout of administration)

8/9/2019 Ani Iabetic Drug Final

8/19

Active Pharmaceutical Ingredient (API)

- Glibenclamide - Glipizide- Glicazide - Glimepride- Phenformin - Metformin

- Combination of Metformin and Glibenclamide- Combination of Metformin and Glipizide- Combination of Metformin and Gliclazide- Combination of Metformin and Glimepride

The quantity of API per tablet is also vary according to type of API and theavailable tablets contains following range of quantity

-0.5mg, 1mg, 1.25mg, 2mg, 3mg, 4mg, 5mg, 6mg, 8mg, 10mg, 15mg,30mg, 40mg, 50mg, 80mg, 100mg, 120mg, 125mg, 250mg, 850mg,

1000mg.

8/9/2019 Ani Iabetic Drug Final

9/19

Anti-diabetic Parental preparations

-Neutral Insulin (Soluble)

-Isophane Insulin (NPH)

-Insulin Zinc Suspension

-Premixed Biphasic Insulin

-Insulin Lispro

-Insulin Glargine

The major players in this market are ELI LILY and

NOVO NORDISK.

8/9/2019 Ani Iabetic Drug Final

10/19

ADVERTISEMENT OF ANTI-DIABETIC AGENTS

Medical representative

Magazine

Web site

Free sampling

Seminars

Brochure

Health check up camp and

counseling

Pharmaceutical fair - IPC

8/9/2019 Ani Iabetic Drug Final

11/19

DISTRIBUTION CHANNEL 1

8/9/2019 Ani Iabetic Drug Final

12/19

DISTRIBUTION CHANNEL 2

8/9/2019 Ani Iabetic Drug Final

13/19

Pricing

vLife saving drugs and under Drug Price Control Order

(DPCO)

v The margin on this kind of product is limited to 10 to

15%

8/9/2019 Ani Iabetic Drug Final

14/19

CONCLUSION

o Spreading globally

o Cross - 250 Million by end of 2010

o Injectable anti diabetic agents

o Oral anti diabetic agents

o Lower profitable margin

8/9/2019 Ani Iabetic Drug Final

15/19

Reference

1. William H. Herman, Ronald E. Aubert, Mohammad A. Ali, Edward

S. Sous andAhmed Badran. Diabetes mellitus in Egypt: risk factors, prevalenceand future burden. EMHJ Volume 3, Issue 1, 1997, Page 144-148.

2. Roberts AB, Baker JR, Metcalf P, et al. Fructosamine comparedwith a glucose load as a screening test for gestational diabetes.

Obstet Gynecol 1990;76:773-775.

3. Business insights

4. 12.17 Company Market Share (%) For Insulin Products for theEuropean Market.

5. Singer DE, Coley CM, Samet JH, et al. Tests of glycemia indiabetes mellitus. Ann Intern Med 1989;110:125-137.

8/9/2019 Ani Iabetic Drug Final

16/19

Thank

You

8/9/2019 Ani Iabetic Drug Final

17/19

8/9/2019 Ani Iabetic Drug Final

18/19

Introduction

8/9/2019 Ani Iabetic Drug Final

19/19

Elementswww.animationfactory.com